Prevalence and Prognosis of Unrecognized Myocardial Infarction Determined by Cardiac Magnetic Resonance in Older Adults

Erik B. Schelbert, MD, MS
Jie J. Cao, MD, MPH
Sigurður Sigurðsson, MS
Thor Aspelund, PhD
Peter Kellman, PhD
Anthony H. Aletras, PhD
Christopher K. Dyke, MD
Gudmundur Thorgeirsson, MD
Gudny Eiriksdottir, MSc
Lenore J. Launer, PhD
Vilmundur Gudnason, MD, PhD
Tamara B. Harris, MD, MS
Andrew E. Arai, MD

The prevalence and prognosis of unrecognized myocardial infarction (MI) in older people with and without diabetes may be higher than previously suspected in population studies.1-4 Advances in MI detection, such as cardiac magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE), are more sensitive than prior methods.5 Asscertaining the prevalence of unrecognized MI (UMI) in these groups is relevant because age and diabetes increase the risks of coronary heart disease.6 Pathologic studies7 indicate that subclinical coronary plaque rupture occurs frequently, particularly in diabetic individuals, which may culminate in a high prevalence of UMI.

Several population studies1-4 have described the prevalence of UMI based on electrocardiography (ECG), but ECG

Context  Unrecognized myocardial infarction (MI) is prognostically important. Electrocardiography (ECG) has limited sensitivity for detecting unrecognized MI (UMI).

Objective  Determine prevalence and mortality risk for UMI detected by cardiac magnetic resonance (CMR) imaging or ECG among older individuals.

Design, Setting, and Participants  ICELAND MI is a cohort substudy of the Age, Gene/Environment Susceptibility–Reykjavik Study (enrollment January 2004-January 2007) using ECG or CMR to detect UMI. From a community-dwelling cohort of older individuals in Iceland, data for 936 participants aged 67 to 93 years were analyzed, including 670 who were randomly selected and 266 with diabetes.

Main Outcome Measures  Prevalence and mortality of MI through September 1, 2011. Results reported with 95% confidence limits and net reclassification improvement (NRI).

Results  Of 936 participants, 91 had recognized MI (RMI) (9.7%; 95% CI, 8% to 12%), and 157 had UMI detected by CMR (17%; 95% CI, 14% to 19%), which was more prevalent than the 46 UMI detected by ECG (5%; 95% CI, 4% to 6%; P < .001). Participants with diabetes (n=337) had more UMI detected by CMR than by ECG (n=72; 21%; 95% CI, 17% to 26%, vs n=15; 4%; 95% CI, 2% to 7%; P < .001). Unrecognized MI by CMR was associated with atherosclerosis risk factors, coronary calcium, coronary revascularization, and peripheral vascular disease. Over a median of 6.4 years, 30 of 91 participants (33%; 95% CI, 23% to 43%) with RMI died, and 44 of 157 participants (28%; 95% CI, 21% to 35%) with UMI died, both higher rates than the 119 of 688 participants (17%; 95% CI, 15% to 20%) with no MI who died. Unrecognized MI by CMR improved risk stratification for mortality over RMI (NRI, 0.34; 95% CI, 0.16 to 0.53). Adjusting for age, sex, diabetes, and RMI, UMI by CMR remained associated with mortality (hazard ratio [HR], 1.45; 95% CI, 1.02 to 2.06, absolute risk increase [ARI], 8%) and significantly improved risk stratification for mortality (NRI, 0.16; 95% CI, 0.01 to 0.31), but UMI by ECG did not (HR, 0.88; 95% CI, 0.45 to 1.73; ARI, −2%; NRI, −0.05; 95% CI, −0.17 to 0.05). Compared with those with RMI, participants with UMI by CMR used cardiac medications such as statins less often (36%; 95% CI, 28% to 43%, or 56/157, vs 73%; 95% CI, 63% to 82%, or 66/91; P < .001).

Conclusions  In a community-based cohort of older individuals, the prevalence of UMI by CMR was higher than the prevalence of RMI and was associated with increased mortality risk. In contrast, UMI by ECG prevalence was lower than that of RMI and was not associated with increased mortality risk.

Trial Registration  clinicaltrials.gov Identifier: NCT01322568

JAMA. 2012;308(9):890-897 www.jama.com

Author Affiliations are listed at the end of this article.
Corresponding Author: Andrew E. Arai, MD, Cardiovascular and Pulmonary Branch, National Heart, Lung,
and Blood Institute, National Institutes of Health, 10 Center Dr, Bldg 10, Room B1D416, MSC 1061, Bethesda, MD 20892 (araia@nih.gov).
has significant limitations, such as limited sensitivity that varies with infarct location, and Q waves may resolve over time. Thus, the true prevalence of UMI may be significantly higher than appreciated in prior epidemiologic studies. Cardiac magnetic resonance with LGE has been extensively validated for the detection of MI, is more sensitive than single-photon emission computed tomography (PET) or positron emission tomography, and therefore is probably more sensitive than ECG. However, increased sensitivity is clinically important when the new test better identifies those at risk for adverse events.

The specific aim of this study was to compare the prevalence and prognostic significance of recognized and unrecognized MI diagnosed with CMR vs ECG in older diabetic and nondiabetic participants in ICELAND MI, a substudy of the Age, Gene/Environment Susceptibility—Reykjavik Study (AGES-Reykjavik). We hypothesized that UMI by CMR (1) would be more prevalent than UMI by ECG, in both diabetic and nondiabetic individuals; (2) would be associated with measures of atherosclerosis; and (3) would be significantly associated with increased mortality risk.

**METHODS**

ICELAND MI is an epidemiologic cohort study of diabetic and nondiabetic individuals. Participants were enrolled from January 2004 to January 2007, recruited from the AGES-Reykjavik Study (n = 5764), a randomly selected population-based cohort of men and women born between 1907 and 1935 who have been followed up in Iceland since 1967 by the Icelandic Heart Association. AGES-Reykjavik was approved by the National Bioethics Committee in Iceland that acts as the institutional review board for the Icelandic Heart Association and by the National Institute on Aging intramural institutional review board. Participants were eligible to participate in ICELAND MI if they provided written informed consent and were ineligible if they could not safely receive CMR scans (eg, they had implanted devices) or gadolinium contrast (eg, they had severe kidney disease). Participants were recruited from AGES-Reykjavik in 2 phases. The first phase involved random recruitment, and a second phase recruited all eligible and willing participants with diabetes.

**Data Elements**

Participants were characterized during 3 clinic visits. Cardiac magnetic resonance studies occurred during a separate examination that included ECG. Participant surveillance has been ongoing since 1967 through the Icelandic Heart Association and provided ascertainment of recognized MI (RMI).

Participants were defined as having an RMI when a history of MI was supported by hospital records or surveillance records. Participants were defined as having a UMI by ECG when there was evidence of MI by ECG criteria (Minnesota codes 1.1.1-1.2.8). Unrecognized MI by CMR meant there was no prior MI by hospital records or by surveillance records, and LGE involved the subendocardium in a coronary distribution. Other “atypical” patterns of LGE were specifically not designated as MI, a strategy that yields sensitivities and specificities greater than 90% for MI detection. Cardiac magnetic resonance studies were interpreted by cardiologists blinded to clinical information.

Participants were further characterized with demographics, risk factors related to atherosclerosis, other comorbidities, biochemical measurements from blood, coronary calcium (Agatston scores), and ECG. Participants were classified as having diabetes according to standard criteria (fasting glucose ≥125 mg/dL; to convert to mmol/L, multiply by 0.0555) or if they were already receiving treatment for diabetes. All-cause mortality was identified by review of hospital records as well as a national mortality index with authentication of all death certificates through September 1, 2011.

**CMR Studies**

Cardiac magnetic resonance scans were performed on a 1.5-T scanner (GE Healthcare) using a 4-element cardiac phased array coil. Typical cine steady-state free precession (SSFP) scan parameters resulted in pixel dimensions of 1.8 × 2.1 mm, a slice thickness of 8 mm with a 3-mm gap, and 30 images per cycle. Standard long-axis and short-axis views were obtained to evaluate global and regional function.

---

©2012 American Medical Association. All rights reserved.

---

**Table 1. Baseline Characteristics of Participants**

<table>
<thead>
<tr>
<th></th>
<th>All Participants (N = 936)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (IQR), y</td>
<td>76 (72-81)</td>
</tr>
<tr>
<td>Female sex, No. (%)</td>
<td>484 (52) [49-55]</td>
</tr>
<tr>
<td>BMI, median (IQR)a</td>
<td>27 (25-30)</td>
</tr>
<tr>
<td>CHD risk factors, No. (%) [95% CI]</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>629 (67) [64-70]</td>
</tr>
<tr>
<td>Family history of MI</td>
<td>334 (36) [33-39]</td>
</tr>
<tr>
<td>Diabetes</td>
<td>337 (36) [33-39]</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>421 (45) [42-48]</td>
</tr>
<tr>
<td>Coronary disease, No. (%) [95% CI]</td>
<td></td>
</tr>
<tr>
<td>Prior MI</td>
<td>91 (10) [8-12]</td>
</tr>
<tr>
<td>Prior coronary revascularization</td>
<td>139 (15) [13-17]</td>
</tr>
<tr>
<td>Peripheral arterial disease, No. (%) [95% CI]</td>
<td></td>
</tr>
<tr>
<td>Stroke, No. (%) [95% CI]</td>
<td>52 (6) [4-7]</td>
</tr>
<tr>
<td>Laboratory results, median (IQR) eGFR, mL/min per 1.73 m²</td>
<td>69 (59-82)</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>208 (178-240)</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>56 (46-68)</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>128 (99-158)</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>98 (75-135)</td>
</tr>
<tr>
<td>Coronary calcium score, Agatstonc</td>
<td>361 (74-974)</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; CHD, coronary heart disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; MI, myocardial infarction.

SI conversion factors: To convert total, HDL, and LDL cholesterol to mmol/L, multiply by 0.0259; triglyceride to mmol/L, multiply by 0.0113.

a Calculated as weight in kilograms divided by height in meters squared.

b Supported by hospital or surveillance records.

c Scores ranged from 0 to 7333. Coronary artery calcification occurs in atherosclerotic arteries and is absent in the normal vessel wall. Higher scores, measured by the Agatston method from computed tomographic scans, correlate with higher risks of coronary events.
The presence of MI was evaluated with a prospective, ECG gated, segmented, phase-sensitive gradient echo inversion recovery sequence approximately 6 to 25 minutes after 0.1 mmol/kg intravenous gadolinium (Magnevist, Berlex). Late gadolinium enhancement was designated MI by consensus of cardiologists experienced in CMR.

**Statistical Analysis**

Results are presented with 95% confidence intervals. We compared categorical variables with the \( \chi^2 \) or Fisher test and continuous variables with the Wilcoxon rank-sum test. McNemar statistic was used to test whether CMR was more likely to detect UMI than ECG. We compared survival curve strata with the log-rank test. Tests for trend used \( \chi^2 \) tests for categorical variables, linear regression for adjusted log coronary artery calcium (CAC) scores, and Kruskal Wallis for data that were not normally distributed.

Binary response variables were further analyzed by Cox regression survival analysis, and continuous variables were analyzed by linear regression. Multivariable Cox models adjusted for variation in key baseline characteristics included in prior epidemiologic studies using ECG: age, sex, diabetes, BMI, and finally UMI by CMR or UMI by ECG. Proportional hazards assumptions were verified by Schoenfeld residuals and time interaction terms. Absolute risk increases were calculated by measuring the survival rate difference before and after exponentiating the 7-year Kaplan-Meier survival rate in the reference group to the power of the adjusted hazard ratio (HR) in the comparison group. We used the integrated discrimination index (IDI) and net reclassification index (NRI) to evaluate the added predictive ability of survival models with the introduction of the UMI by CMR variable.\(^\text{19,20}\)

Follow-up was enhanced by hospital record information, a national mortality index with authentication of all death certificates, a minimum data set for nursing home patients, and a minimum data set for home-care patients. Coronary artery calcium was analyzed on the natural logarithm scale, \( \ln(CAC+1) \). Two-sided \( P \) values less than .05 were considered significant. We used SAS version 9.2 (SAS Institute) to analyze the data.

**RESULTS**

For phase 1, 839 individuals were invited and 702 enrolled. In phase 2, 421 participants with diabetes were invited and 290 people enrolled (1005 total). Thirty-five participants declined CMR. Of those who underwent CMR (n=970), 34 participants had nondiagnostic CMR scans due to arrhythmia or inability to hold breath (n=14), claustrophobia (n=7), inability to gate cardiac images (n=3), technical issues with reconstruction and data transfer (n=9), or artifact from spinal implants (n=1). These participants were excluded, leaving a final cohort of 936 participants. Survivors were followed up for a median of 6.6 years (range, 4.6-7.7 years).

The median age was 76 years (interquartile range [IQR], 72-81 years; range, 68-94 years), and 52% (95% CI, 49%-55%) were women (484/936). Baseline characteristics are summarized in Table 1. ICELAND MI participants randomly selected in phase 1 had characteristics almost identical to the AGES-Reykjavik participants (Table 1, available at http://www.jama.com).

**Prevalence of MI Using CMR and ECG**

A total of 91 of 936 participants (9.7%; 95% CI, 8%-12%) had RMI, and the prevalence of UMI by CMR was even higher (157/936; 17%; 95% CI, 14%-19%; \( P < .001 \)), as shown in Table 2. Those with diabetes had a higher prevalence of UMI by CMR than those without diabetes (n=72; 21%; 95% CI, 17%-26%, vs n=85; 14%; 95% CI, 11%-17%, \( P < .001 \)). Examples of CMR images are shown in Figure 1.

Cardiac magnetic resonance detected 157 UMI, which was more than the 46 UMI detected by ECG (prevalence by CMR, 17%; 95% CI, 14%-19%; vs ECG, 5%; 95% CI, 4%-6%, respectively, \( P < .001 \)). There were 27 participants (3%; 95% CI, 2%-4%) with UMI by ECG who exhibited no MI on CMR, and there were 138 individuals (15%; 95% CI, 12%-17%) who had UMI by CMR yet did not meet criteria for...
UMI by ECG ($P<.001$). In the randomly sampled cohort (n=670), 61 participants (9%; 95% CI, 7%-11%) had RMI and 97 (14%; 95% CI, 12%-17%) had UMI by CMR whereas only 35 (5%; 95% CI, 4%-7%) had UMI by ECG, significantly less than UMI by CMR ($P<.001$).

**Associations With Atherosclerosis and Diabetes**

Coronary artery disease risk factors were more prevalent in participants with UMI compared with those with no MI. Compared with those without MI, participants with UMI were more frequently male, were slightly older, and had more hypertension and diabetes (TABLE 3). Similarly, those with UMI had more atherosclerosis with significantly higher coronary calcium scores than those without MI (Table 3). Overall, coronary calcium showed a significant graded relationship to the presence of MI, in which participants with UMI had coronary calcium scores intermediate between those without MI and those with clinically recognized MI (Table 3).

There was also a graded relationship between the likelihood of revascularization and MI status (Table 3). For 26 of 72 participants with diabetes (36%; 95% CI, 25%-47%) and 18 of 85 without diabetes (21%; 95% CI, 12%-30%) who had UMI had prior coronary revascularization. Excluding those with prior coronary revascularization (n=139), participants with and without diabetes still had high rates of UMI (46/273 or 17%; 95% CI, 12%-21%, vs 67/524 or 13%; 95% CI, 10%-16%, respectively). Thus, UMI was associated with atherosclerosis risk factors, coronary calcium, and treatment for atherosclerosis. Other characteristics of those with UMI by CMR are provided in Table 3.

**Prognosis of RMI and UMI**

Over a median follow-up of 6.4 years (IQR, 4.9-7.0 years), 30 of 91 participants with RMI died (33%; 95% CI, 23%-43%), and 44 of 157 with UMI by CMR died (28%; 95% CI, 21%-35%).
which were both significantly higher rates than the 17% (95% CI, 15%-20%) with no MI who died (119/688). Both UMI by CMR and RMI had higher mortality compared with those without MI (HR, 1.81; 95% CI, 1.28 to 2.56; absolute risk increase, 13%, and HR, 2.20, 95% CI, 1.48 to 3.29, absolute risk increase, 19%, respectively). Unrecognized MI by CMR improved mortality risk stratification beyond RMI (category-free NRI, 0.34; 95% CI, 0.16 to 0.53). Unrecognized MI detected by ECG was not associated with higher mortality (HR, 0.95; 95% CI, 0.49 to 1.87; absolute risk increase, −1%). Unadjusted Kaplan-Meier survival curves for those without MI, those with UMI by CMR, and those with clinically recognized MI are shown in Figure 2. Five years after the CMR scan, the absolute mortality rates were 12% (95% CI, 9%-14%) for those without MI, 23% (95% CI, 16%-29%) with UMI by CMR, and 23% (95% CI, 17%-30%) in those with RMI. This culminated in approximately a 10% difference in absolute mortality rates between those with and without MI (eTable 2).

After adjusting for age, sex, diabetes, and RMI, UMI by CMR remained associated with mortality (HR, 1.45; 95% CI, 1.02 to 2.06; absolute risk increase, 8%), but UMI by ECG was not associated with mortality (HR, 0.88; 95% CI, 0.45 to 1.73; absolute risk increase, −2%). Similarly, UMI by CMR significantly improved the classification of those at risk for mortality (category-free NRI, 0.16; 95% CI, 0.01 to 0.31; P = .04), but UMI by ECG did not (NRI, −0.05; 95% CI, −0.17 to 0.03). Finally, UMI by CMR significantly improved mortality risk stratification (absolute IDI, 0.008; 95% CI, 0.004 to 0.013; P < .001), but UMI by ECG did not improve mortality risk stratification (IDI; 0.00; 95% CI, −0.001 to 0.001; P = .71).

**Treatment Differences**

We observed more use of aspirin, β-blockers, and statin medications in those with UMI by CMR compared with those without MI. Yet the use of cardiac medications was significantly less in those with UMI compared with those with RMI (Table 3). Roughly half of those with UMI were taking aspirin, whereas less than half were taking statins or β-blockers.

**COMMENT**

Using CMR with a conservative interpretation scheme to detect MI in a cohort of community-dwelling older people, we found a high overall prevalence of UMI. More participants had UMI (17%) than RMI (9.7%), resulting in a much higher fraction of the population being identified as having an MI (26%). Individuals with diabetes had a particularly high prevalence of unrecognized MI.

---

**Table 3. Associations of Recognized MI and Unrecognized MI Detected by CMR With Diabetes or Atherosclerosis**

<table>
<thead>
<tr>
<th></th>
<th>No MI (n = 688)</th>
<th>Unrecognized MI (n = 157)</th>
<th>Recognized MI (n = 91)</th>
<th>P Value for Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Women, No. (%) [95% CI]</strong></td>
<td>395 (57) [54-61]</td>
<td>67 (36) [29-44]</td>
<td>32 (35) [25-45]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>Age, median (IQR), y</strong></td>
<td>76 (72-80)</td>
<td>77 (74-83)</td>
<td>78 (74-82)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>Laboratory results, median (IQR)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>eGFR, mL/min per 1.73 m²</td>
<td>70 (59-82)</td>
<td>68 (58-81)</td>
<td>64 (53-74)</td>
<td>.004</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>216 (185-243)</td>
<td>201 (170-239)</td>
<td>178 (154-205)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>58 (47-69)</td>
<td>53 (45-63)</td>
<td>51 (42-59)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>130 (106-162)</td>
<td>120 (91-157)</td>
<td>98 (77-128)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>95 (73-132)</td>
<td>108 (79-148)</td>
<td>104 (73-145)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>Coronary calcium score, Agatston</strong></td>
<td>227 (60-693)</td>
<td>792 (263-1713)</td>
<td>1133 (654-2159)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>Medications, No. (%) [95% CI]</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>215 (31) [28-35]</td>
<td>81 (62) [44-59]</td>
<td>74 (81) [73-89]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Statins</td>
<td>153 (22) [20-25]</td>
<td>66 (36) [28-43]</td>
<td>66 (73) [63-82]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>ACE inhibitors or ARBs</td>
<td>132 (19) [16-22]</td>
<td>27 (20-34)</td>
<td>26 (29-19-38)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>CMR characteristics, median (IQR)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ejection fraction %</td>
<td>63 (58-67)</td>
<td>60 (51-65)</td>
<td>53 (42-61)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>End diastolic volume index, mL/m²</td>
<td>98 (87-111)</td>
<td>109 (92-124)</td>
<td>113 (96-147)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Left ventricular mass index, g/m²</td>
<td>72 (62-83)</td>
<td>83 (70-95)</td>
<td>83 (69-102)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blockers; BMI, body mass index; CHD, coronary heart disease; CMR, cardiac magnetic resonance; ECG, electrocardiography; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; MI, myocardial infarction.

aSI conversion factors: To convert total, HDL, and LDL cholesterol to mmol/L, multiply by 0.0259; triglyceride to mmol/L, multiply by 0.0113.

bSignificantly different compared with individuals without MI (P < .05). For coronary calcium, these differences persisted even after adjusting for age and sex.

cCalculated as weight in kilograms divided by height in meters squared.

dSignificantly different compared with those with recognized MI (P < .05). For coronary calcium, these differences persisted even after adjusting for age and sex.

Scores ranged from 0 to 7333. Coronary artery calcification occurs in atherosclerotic arteries and is absent in the normal vessel wall. Higher scores, measured by the Agatston method from computed tomographic scans, correlate with higher risks of coronary events.
of UMI (21%), underscoring the designation of diabetes as a coronary risk equivalent, but the pattern of more UMI than RMI was also true in those without diabetes.

Participants with UMI by CMR had higher coronary calcium, a higher prevalence of atherosclerotic disease, and a higher prevalence of traditional risk factors compared with those with no MI. Cardiac magnetic resonance was more sensitive than ECG in detecting UMI. Unrecognized MI detected by CMR was associated with subsequent mortality over 6 to 7 years, but UMI detected by ECG was not. Compared with those with RMI, participants with UMI by CMR received fewer prescriptions for medications used to prevent cardiovascular events. Considering the prevalence of UMI (17%) was higher than the prevalence of RMI (10%), many people might conceivably benefit from more intensive preventive therapy after UMI, but this hypothesis remains untested.

Several factors may contribute to the high prevalence of UMI. First, subclinical coronary plaque rupture occurs frequently, particularly in diabetic individuals. Cardiac magnetic resonance may detect the myocardial sequelae of coronary plaque rupture or coronary plaque erosion that either spontaneously reperfused or were nonocclusive. Second, symptom variation in acute MI may lead patients or their clinicians to attribute MI symptoms to noncardiac causes. Third, given their propensity to be clinically detected, RMI may be more severe than UMI and impart greater lethality. Survivor bias may also have increased the proportion of those with UMI in this study, but survivors are the only people eligible for post-MI secondary prevention.

The high prevalence of UMI highlights the advantages of using CMR for detection in epidemiology studies. Although the prevalence of UMI by ECG was similar to that in prior population studies, ECG was much less sensitive for detecting UMI than CMR. Prior population studies probably underestimated the prevalence of MI and particularly UMI because they relied on ECG for detection. The mortality risk associated with UMI by ECG is less than previous reports; smaller sample size, survivor bias, and different health care practices may be factors.

The increased mortality risk associated with UMI detected by CMR in a community-based cohort of older individuals is an important finding of this study, since we document a high prevalence of UMI. In fact, we found that the majority of all MIs were clinically unrecognized, suggesting a significant public health burden. This association between prevalent UMI and mortality is novel, because prior epidemiology studies relying on ECG data indicated that a minority of MIs are clinically unrecognized. Our study is also the first epidemiology study, to our knowledge, to associate coronary calcium with evident MI on CMR LGE images. Although another smaller study using LGE in 248 individuals also reported that most MIs were unrecognized, the study sampled only 75-year-old individuals and could not determine the association with mortality controlling for age.

Unrecognized MI appears to represent an intermediate phenotype in the evolution of coronary heart disease, given its graded association with atherosclerosis risk factors, coronary calcium, overt atherosclerosis, and subsequent mortality risk.

Other studies have associated UMI identified by CMR with adverse outcomes, but these studies were not community-based epidemiology studies; instead, they were conducted in referral populations with higher baseline risk and inherent biases. The relative risk of UMI may be higher in these studies due to referral biases not present in our community-based population study. Nonetheless, the current study indicates that the adverse outcomes associated with UMI extend to the community. Our study also indicates that CMR is more robust at detecting MI and more strongly associated with mortality compared with ECG—an observation with important implications for future epidemiology studies of UMI.

Several lines of evidence establish that the designation of UMI represents true MI. First, CMR scans were interpreted conservatively. Specifically, atypical patterns of enhancement seen with conditions unrelated to coronary disease were not designated as MI. Second, the prevalence of risk factors for coronary heart disease or established atherosclerotic disease documented multiple associations of UMI by CMR with atherosclerosis. Kim et al have also shown associations between coronary disease and UMI. Furthermore, the association between UMI de-
ected by LGE and mortality also supports the diagnosis of MI.

This investigation also suggests limitations in current prevention strategies. Herein we report a burden of MI in community-dwelling older individuals that is higher than previously appreciated. The burden of UMI was higher than the total burden of recognized MI, and prescription of cardioprotective medications was less than for participants with RMI. The high prevalence of MI specifically in individuals with diabetes confirms their increased vulnerability. Less than one-third of those with UMI by CMR had prior revascularization to establish coronary disease and trigger secondary prevention strategies. Detection of UMI by CMR may provide an opportunity to optimize treatment for these vulnerable individuals, but further study is needed to assess this.

The AGES-Reykjavik cohort provides results that are most applicable to white participants and may not extend to other ethnicities. The sensitivity of CMR for detecting chronic MI using a 0.1-mmol/L gadolinium contrast dose in our study may be lower compared with higher doses. However, if our study actually had low sensitivity, then the true prevalence of MI would be higher. Mitigating the issue of contrast dose, the phase-sensitive LGE method used in this study has better signal-to-noise ratio at low-contrast doses than conventional LGE methods. In the minority of participants with both UMI and prior coronary revascularization, we could not ascertain whether UMI occurred independently or as a clinically unappreciated consequence of revascularization. Nonetheless, revascularization complications do not explain the high prevalence of UMI because the prevalence of UMI in participants with and without diabetes remained high even after excluding prior coronary revascularization. We also did not examine more subtle ECG changes that may be associated with MI. Risk adjustment was limited. This study was designed to demonstrate comparable prognoses between UMI and RMI; it was not powered to permit extensive risk adjustment for all baseline differences.

CONCLUSIONS
Older individuals in the community had a high prevalence of MI, especially those with diabetes. Most MI were unrecognized, despite associations with atherosclerosis, risk factors, and health care advances. Cardiac magnetic resonance with LGE detected more UMI and was more strongly associated with mortality than ECG. Unrecognized MI detected by CMR with LGE was associated with mortality similar to recognized MI. Participants with UMI received fewer cardiac medications than those with RMI.

Author Affiliations: National Heart, Lung, and Blood Institute (Dr Schelbert, Cao, Kellman, Aletras, Dyke, and Ari) and National Institute on Aging (Drs Launer and Harris), National Institutes of Health, Bethesda, Maryland; Icelandic Heart Association, Kopavogur, Iceland (Mr Sigurdsson and Drs Aspelund, Eiriksdottir, and Gudnason); University of Iceland, Reykjavik, Iceland (Drs Aspelund, Thorgeirsson, and Gudnason); University of Pittsburgh Medical Center Heart and Vascular Institute, Pittsburgh, Pennsylvania (Dr Schelbert); St Francis Hospital, State University of New York at Stony Brook, Roslyn (Dr Cao); and Alaska Heart Institute, Anchorage (Dr Dyke).

Author Contributions: Dr Ariad had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Aletras, Dyke, Thorgeirsson, Gudnason, Harris, Ariad.

Acquisition of data: Cao, Sigurdsson, Kellman, Aletras, Dyke, Gudnason, Harris.

Analysis and interpretation of data: Schelbert, Cao, Aspelund, Dyke, Thorgeirsson, Launer, Ariad.

Drafting of the manuscript: Schelbert, Aspelund, Aletras, Dyke, Ariad.

Critical revision of the manuscript for important intellectual content: Cao, Sigurdsson, Kellman, Aletras, Dyke, Thorgeirsson, Eiriksdottir, Launer, Gudnason, Harris.

Statistical analysis: Schelbert, Aspelund, Aletras, Dyke.

Obtained funding: Eiriksdottir, Launer, Gudnason, Harris, Ariad.

Administrative, technical, or material support: Cao, Sigurdsson, Aletras, Thorgeirsson, Eiriksdottir, Harris, Ariad.

Study supervision: Cao, Dyke, Gudnason, Ariad.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Funding/Support: This study was funded by the National Heart, Lung, and Blood Institute Intramural Research Program (Z01 HL004607-08 CE), the National Institute on Aging Intramural Research Program (N1AG-12100), Hjartavenn (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament).

The study was approved by the Icelandic National Bioethics Committee (VSN: 06-063) and the Medstar Research Institute (project 2003-145). Dr Schelbert is supported by a T. Franklin Williams Scholarship Award, funding for which is provided by AtlanticPhilanthropies, the John A. Hartford Foundation, the Association of Specialty Professors, and the American Heart Association. Dr Cao is supported by an American Heart Association Grant-in-Aid (10GRNT4580000).

Role of the Sponsor: The funding sources had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.


REFERENCES
15. Mahrohldt H, Wagner A, Judd RM, Sechtem U,
Experimentation must always be devised in view of a preconceived idea, no matter if the idea be not very clear nor very well-defined. As for noting the results of the experiment, . . . we must here, as always, observe without a preconceived idea.

——Claude Bernard (1813-1878)